Literature DB >> 12450690

Candidate peptide vaccine induced protection against classical swine fever virus.

Xiao-Nan Dong1, Ke Wei, Zu-Qiang Liu, Ying-Hua Chen.   

Abstract

Former investigations demonstrated that the envelope glycoprotein E2 could protect pigs from classical swine fever virus (CSFV). Based on these findings, we prepared synthetic peptide vaccine using E2 N-terminal antigenic units B/C and hoped to induce protective activity against lethal challenge of virulent CSFV strain Shimen. Five overlapped peptides sequence-covering amino acids 693-777 on E2 of Shimen were synthesized and then conjugated with bovine serum albumin (BSA), respectively. In the vaccination course, the candidate peptide vaccines in combination (multi-peptide vaccine (MPV)) were applied for immunization of pigs (n=10) and induced strong antibody response against CSFV. It is subsequently demonstrated that this peptide vaccine could provide immunized pigs complete protection against lethal CSFV challenge as C-strain does, while all non-immunized pigs in negative control group manifested obvious typical symptoms and died during the second and third weeks after viral challenge. In order to confirm the neutralizing activity of the polyclonal antibodies induced by MPV, neutralization assay were carried out on rabbits. The live C-strain alone could ordinarily induce typical fever on rabbits. The typical fever of rabbits induced by the live C-strain could be inhibited by pre-incubation with the anti-sera (dilution 1:4 and 1:16) induced by MPV, but not inhibited by pre-incubation with the same anti-sera from which the antibodies against five peptides were removed by peptide-specific affinity chromatography, which indicates that these peptide-specific antibodies in the anti-sera induced by MPV provided protective activity against CSFV. Our finding provides a new way to develop marker vaccine against CSFV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450690     DOI: 10.1016/s0264-410x(02)00466-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.

Authors:  Hui Xuan Lim; Jianhua Lim; Chit Laa Poh
Journal:  Med Microbiol Immunol       Date:  2021-01-30       Impact factor: 3.402

2.  In silico prediction of peptides binding to multiple HLA-DR molecules accurately identifies immunodominant epitopes from gp43 of Paracoccidioides brasiliensis frequently recognized in primary peripheral blood mononuclear cell responses from sensitized individuals.

Authors:  Leo Kei Iwai; Márcia Yoshida; John Sidney; Maria Aparecida Shikanai-Yasuda; Anna Carla Goldberg; Maria Aparecida Juliano; Jurgen Hammer; Luiz Juliano; Alessandro Sette; Jorge Kalil; Luiz Rodolpho Travassos; Edecio Cunha-Neto
Journal:  Mol Med       Date:  2003 Sep-Dec       Impact factor: 6.354

3.  Multiple linear B-cell epitopes of classical swine fever virus glycoprotein E2 expressed in E.coli as multiple epitope vaccine induces a protective immune response.

Authors:  Bin Zhou; Ke Liu; Yan Jiang; Jian-Chao Wei; Pu-Yan Chen
Journal:  Virol J       Date:  2011-07-30       Impact factor: 4.099

4.  In planta production of two peptides of the Classical Swine Fever Virus (CSFV) E2 glycoprotein fused to the coat protein of potato virus X.

Authors:  Gianpiero Marconi; Emidio Albertini; Pierluigi Barone; Francesca De Marchis; Chiara Lico; Carla Marusic; Domenico Rutili; Fabio Veronesi; Andrea Porceddu
Journal:  BMC Biotechnol       Date:  2006-06-22       Impact factor: 2.563

Review 5.  Development of multi-epitope peptide-based vaccines against SARS-CoV-2.

Authors:  Hui Xuan Lim; Jianhua Lim; Seyed Davoud Jazayeri; Sibrandes Poppema; Chit Laa Poh
Journal:  Biomed J       Date:  2020-10-01       Impact factor: 4.910

Review 6.  Peptide-Based Vaccines: Foot-and-Mouth Disease Virus, a Paradigm in Animal Health.

Authors:  Mar Forner; Rodrigo Cañas-Arranz; Sira Defaus; Patricia de León; Miguel Rodríguez-Pulido; Llilianne Ganges; Esther Blanco; Francisco Sobrino; David Andreu
Journal:  Vaccines (Basel)       Date:  2021-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.